The SUMO family in vertebrates includes at least three distinct proteins (SUMO-1, -2, and -3) that are added as post-translational modifications to target proteins. A considerable number of SUMO-1 target proteins have been identified, but little is known about SUMO-2. A stable HeLa cell line expressing His 6 -tagged SUMO-2 was established and used to label and purify novel endogenous SUMO-2 target proteins. Tagged forms of SUMO-2 were functional and localized predominantly in the nucleus. His 6 -tagged SUMO-2 conjugates were affinity-purified from nuclear fractions and identified by mass spectrometry. Eight novel potential SUMO-2 target proteins were identified by at least two peptides. Three of these proteins, SART1, heterogeneous nuclear ribonucleoprotein (RNP) M, and the U5 small nuclear RNP 200-kDa helicase, play a role in RNA metabolism. SART1 and heterogeneous nuclear RNP M were both shown to be genuine SUMO targets, confirming the validity of the approach.
activity have been characterized, including Ran-binding protein-2, Pc2, and members of the PIAS family (19, 34 -41) .
Sumoylation is a reversible process. In addition to the SUMO conjugation machinery, a set of specific and highly active proteases can remove SUMO from target proteins (42) (43) (44) (45) (46) (47) (48) (49) . Interestingly, these proteases exhibit unique tissue-specific expression and subcellular localization patterns, suggesting that they have non-overlapping functions (44, 45, (47) (48) (49) (50) . SUMO proteases also play a role in the maturation of SUMO precursors. All three SUMO family members are translated as larger precursors, and SUMO proteases remove C-terminal amino acids from these precursors to expose the SUMO diglycine motif required for conjugation to target proteins (22, 43, 45, 47) .
The single SUMO gene in both Saccharomyces cerevisiae (51) and Caenorhabditis elegans (52, 53) is essential for viability, indicating that sumoylation is an essential process. Consistent with this, several genes encoding SUMO-conjugating enzymes and SUMO proteases are also essential (22, 42, 52, 53) . Sumoylation is also likely to be an essential cellular process for higher eukaryotic cells because Ubc9 is required for the viability of chicken DT40 cells (54) .
Many target proteins have been identified for SUMO-1, including RanGAP1, PML, Sp100, p53, and IB␣ (9, 10, 14, 55, 56) . In contrast, the only proteins reported as targets for SUMO-2 are PML, Sp3, heat shock factor-1, thymine DNA glycosylase, histone deacetylase-4, p300, and lymphoid enhancer factor-1 (8, 19, (57) (58) (59) (60) (61) (62) . Most recently, Xenopus topoisomerase II was shown to be a substrate for SUMO-2 specifically during M phase, thereby affecting the interaction of topoisomerase II with chromatin (63) . Here, we report on a set of novel endogenous target proteins for SUMO-2, identified using proteomics coupled with an affinity selection strategy based on a stable cell line expressing low levels of His 6 -SUMO-2.
EXPERIMENTAL PROCEDURES
Plasmids Constructs and Antibodies-The cDNA for SUMO-2 was amplified by PCR using expressed sequence tag AI814334 (Medical Research Council Rosalind Franklin Centre for Genomics Research) and specific primers with BamHI and Asp718 restriction sites on the 5Ј-and 3Ј-primers, respectively. The amplified fragment was subsequently inserted into the BamHI and Asp718 sites of pEYFP-C1 (Clontech). The previously published plasmid pcDNA3-HA-SUMO-2 (59) was used to obtain a BamHI-EcoRI fragment encoding SUMO-2. This DNA fragment was cloned into similar sites of the pcDNA3-His 6 vector (56) to generate the pcDNA3-His 6 -SUMO-2 construct. This vector was digested with HindIII, blunt-ended using T4 DNA polymerase, and finally digested with EcoRI. The corresponding DNA fragment encoding His 6 -SUMO-2 was subcloned into the EcoRV and EcoRI sites of the pIRESpuro2 vector (Clontech). The cDNA for SART1 was amplified by PCR using expressed sequence tag BG257275 (Medical Research Council Rosalind Franklin Centre for Genomics Research) and specific extended primers compatible with the Gateway system (Invitrogen). The amplified fragment was subsequently inserted into pDON207, and EYFP-SART1 and T7-SART1 expression constructs were obtained using standard Gateway methods.
Peptide antibody 2277 against SUMO-2 was generated in rabbit using the sequence MEDEDTIDVFQQQTG (Eurogentec). Both serum and affinity-purified antibody were used. Polyclonal antibody NRD.1 raised against full-length SUMO-2 was obtained from Zymed Laboratories Inc. (South San Francisco, CA). A previously published polyclonal antibody against SUMO-2 (7), generously provided by Dr. H. Saitoh (Picower Institute for Medical Research, Manhasset, New York), was used during initial studies. Note that the anti-SUMO-2 antibodies also recognize SUMO-3 because these SUMO family members are nearly identical. Other antibodies used were anti-PML monoclonal antibody 5E10 (a generous gift from Dr. R. van Microscopy and Image Analysis-Cells were grown on glass coverslips and fixed for 10 min in 3.7% paraformaldehyde at 37°C in 60 mM PIPES, 25 mM HEPES, 10 mM EGTA, and 2 mM MgCl 2 (pH 6.9) (64). Subsequent manipulations were carried out at room temperature. Permeabilization was carried out for 20 min in phosphate-buffered saline containing 0.5% Triton X-100. Cells were blocked with 10% goat serum for 30 min if required and then incubated with primary antibodies for 1 h, washed, and incubated with secondary antibodies for 1 h. DNA was stained with DAPI (Sigma) at 0.3 g/ml. After washing, cells were mounted in Vectashield (Vector Laboratories).
Antibody 2277 (1:2000), antibody 5E10 (1:10) and anti-His 5 antibody (1:50) were the primary antibodies used. Fluorescein isothiocyanate-, TRITC-, and Texas Red-conjugated secondary antibodies (1:350; Jackson ImmunoResearch Laboratories, Inc.) were used. Three-dimensional images and sections were recorded on a Zeiss Axiovert S100 2TV DeltaVision Restoration microscope (Applied Precision) using a Zeiss Planachromat (100 ϫ 1.40 nuclear aperture objective) and a CCD-1300-Y/HS camera (Roper Scientific). Images were captured and processed by constrained iterative deconvolution using SoftWorx (Applied Precision). Images presented here are maximal intensity projections of Z stacks.
Purification of SUMO-2 Conjugates-Proteins conjugated to His 6 -SUMO-2 were purified using a previously published method to enrich for nuclear bodies and RNA (65 or control parental HeLa) were isolated by trypsinization and washed twice with ice-cold phosphate-buffered saline. Nuclei were isolated and washed with cytoskeletal extraction buffer (10 mM PIPES (pH 6.8), 300 mM sucrose, 100 mM NaCl, 3 mM MgCl 2 , 1 mM EGTA, and 0.5% Triton X-100). Subsequently, nuclei were digested with DNase I (Worthington) in buffer containing 10 mM PIPES (pH 6.8), 300 mM sucrose, 50 mM NaCl, 3 mM MgCl 2 , 1 mM EGTA, and 0.5% Triton X-100. Chromatin was extracted using buffers containing 250 mM (NH 4 ) 2 SO 4 and 1 M NaCl or 2 M NaCl plus 10 mM PIPES (pH 6.8), 150 mM sucrose, 3 mM MgCl 2 , and 1 mM EGTA. All steps were performed at 4°C, and buffers contained EDTA-free complete protease inhibitor mixture (Roche Applied Science). Subsequently, extracted fractions were solubilized in lysis buffer containing 8 M urea, 100 mM Na 2 HPO 4 /NaH 2 PO 4 , 10 mM Tris-HCl (pH 8.0), 10 mM ␤-mercaptoethanol, 20 mM imidazole, and EDTA-free complete protease inhibitor mixture. His 6 -SUMO-2 conjugates were enriched on Ni 2ϩ -nitrilotriacetic acid-agarose beads (QIAGEN Inc.). Beads were successively washed at room temperature with 10 column volumes of first lysis buffer, then buffer A (8 M urea, 100 mM Na 2 HPO 4 / NaH 2 PO 4 , 10 mM Tris-HCl (pH 6.3), 0.2% Triton X-100, and 10 mM ␤-mercaptoethanol), then buffer A lacking Triton X-100, then lysis buffer plus 0.1% Triton X-100, and finally buffer A lacking Triton X-100. Conjugates were eluted at room temperature in 0.2 column volumes of lysis buffer containing 200 mM imidazole. For experiments carried out to confirm the presence of hnRNP M and SART1 in the His 6 -SUMO-2-enriched fraction, cytoskeletal extraction buffer-isolated nuclei were lysed in lysis buffer and sonicated prior to the pull-down of His 6 -SUMO-2 conjugates.
Electrophoresis and Immunoblotting-Protein samples were sizefractionated on Novex 4 -12% BisTris gradient gels using MOPS buffer (Invitrogen) and subsequently transferred onto Hybond-C extra membranes (Amersham Biosciences) using a submarine system (Invitrogen). Blots were stained for total protein using Ponceau S (Sigma). After blocking with phosphate-buffered saline containing 0.1% Tween 20 and 5% milk powder, the membranes were incubated with anti-SUMO-2 antibody (1:1000), antibody 5E10 (1:100), antibody D2-1F7 (1:5000), or antibody 1814460 (1:1000). Anti-His 5 antibody was used according to the instructions of the manufacturer. The secondary antibodies used were anti-rabbit (1:2000) and anti-mouse (1:5000) horseradish peroxidase antibodies (Pierce). Bound antibodies were detected via chemilu-minescence with ECL Plus (Amersham Biosciences).
Mass Spectrometry-Both isolated SUMO conjugates and control samples (200-l total volume) were reduced in lysis buffer lacking Triton X-100 by addition of 0.5 g of dithiothreitol, alkylated by addition of 2 g of iodoacetamide, and digested with endoproteinase Lys-C for 4 h and with trypsin for 8 h after dilution with 50 mM NH 4 HCO 4 (pH 8.0). The resulting peptide mixtures were acidified by A-buffer (0.5% acetic acid and 0.02% heptafluorobutyric acid) and desalted and concentrated using precolumns packed with poros R2 and oligo R3 reversephase material. The partially lyophilized eluate was reconstituted in A-buffer and pressure-loaded onto a pulled fused silica capillary with a 100-m inner diameter and an 8-m tip opening (New Objective) filled with Vydac 218MSB3 3-m reverse-phase material. Peptides were eluted directly into a quadrupole time-of-flight mass spectrometer (MDS Sciex) with a 90-min linear gradient of 5-60% buffer B containing 80% acetonitrile, 0.5% acetic acid, and 0.02% heptafluorobutyric acid at a flow rate of 200 l/min from a cross-flow splitter connected to an HPLC system (Agilent) and a high voltage power supply. Mass spectrometry and tandem mass spectrometry measurements were acquired automatically for 1 and 1.5 s, respectively. Precursor ions were dynamically excluded for 60 s. Scripts in Analyst created a peak list on the basis of the acquired product ion spectra. A combined peak list was searched in the International Protein Index Database 2 using the Mascot program (Matrix Science). Iterative calibration algorithms on the basis of identified peptides were used to achieve an average absolute mass accuracy of better than 20 ppm in both precursor and product ions. Identified peptides that either were not unique or had a score of Ͻ15 were removed. Proteins identified with a combined peptide score of Ͼ60 were considered significant, and lower scoring proteins were manually verified or rejected. Protein abundance ratios between the two samples were estimated from the abundance of each peptide calculated from the area of the extracted ion current peak.
SUMO Conjugation Assays-In vitro SUMO conjugation assays were performed in 10-l volumes containing 0.11 M SAE1/2, 2 mM ATP, 1.2 units/ml inorganic pyrophosphatase, 5 mM MgCl 2 , 50 mM Tris-HCl (pH 7.5), 1 M Ubc9, and 5 M SUMO-2. SART1 sumoylation was carried out using in vitro transcribed and translated SART1. Assays were incubated for 3 h at 37°C before addition of SDS sample buffer containing ␤-mercaptoethanol for gel analysis (59) .
RESULTS

Generation and Characterization of Stable Tagged SUMO-2
Cell Lines-To characterize targets for SUMO-2 and their localization, we generated HeLa cell lines stably expressing fusions of SUMO-2 to either a His 6 tag (to purify biochemical quantities of SUMO-2 conjugates) or YFP tag (to visualize the SUMO-2 subcellular distribution in living cells). The fusions were made to the N terminus of SUMO-2 because conjugation of SUMO-2 to target proteins involves reaction of its C terminus. Plasmids pHis 6 -SUMO-2 and pEYFP-SUMO-2 (shown as a schematic in Fig. 1A ) were transfected into HeLa cells, and stable clones were selected (see "Experimental Procedures") to avoid overexpression artifacts. Following selection, representative clones were characterized to identify the expression levels and localization patterns of the respective SUMO-2 fusion proteins, and the resulting cell lines were labeled as HeLa YFP-SUMO-2 and HeLa His6-SUMO-2 ( Fig. 1, B and C) . In both cases, the fusion proteins were expressed at similar levels compared with endogenous SUMO-2 and showed identical subnuclear localization patterns as revealed by immunoblotting (Fig. 1, B and C) and fluorescence microscopy (Fig. 2) . The tagged SUMO-2 molecules also showed similar fractionation properties compared with endogenous SUMO-2, and analysis by fluorescence-activated cell sorting further indicated that expression of tagged exogenous SUMO-2 did not compromise cell viability or progression through the cell cycle (data not shown).
It was important to verify that the tagged forms of SUMO-2 were actively conjugated to target proteins. We therefore analyzed the pattern of SUMO-2-conjugated proteins present in cell lysates prepared either from control HeLa cells or from clones HeLa YFP-SUMO-2 and HeLa His6-SUMO-2 ( Fig. 1, B and C) . Each lysate was separated by SDS-PAGE, transferred to a membrane, and probed with antibodies against both tags and against SUMO-2. In all cells, only low levels of unconjugated endogenous SUMO-2 were detected (Fig. 1, B and C, arrows indicate free SUMO-2). Most of the SUMO-2 signal was present in high molecular mass conjugates for the control HeLa cells and both tagged cell lines. However, we observed a higher level 2 Available at www.ebi.ac.uk/IPI/IPIhelp.html.
FIG. 1. Stable expression of EYFP-SUMO-2 and His 6 -SUMO-2 in HeLa cells.
A, schematic of SUMO-2 fusion constructs. SUMO-2 was fused at its N terminus to either EYFP or 6 consecutive histidines. B, HeLa EYFP-SUMO-2 cells express tagged SUMO-2 that is conjugated to target proteins. Whole cell extracts of the stable HeLa EYFP-SUMO-2 cell line and control HeLa cells were separated by SDS-PAGE, transferred to a membrane, and probed using an antibody directed against EYFP (YFP lanes) or SUMO-2 (SUMO-2 lanes). C, HeLa His6-SUMO-2 cells express His 6 -tagged SUMO-2 that is conjugated to target proteins. Whole cell extracts of the stable HeLa His6-SUMO-2 cell line and control HeLa cells were separated by SDS-PAGE in nonadjacent lanes, transferred to a membrane, and probed using an antibody to detect both the His 6 tag (His lanes) and SUMO-2 (SUMO-2 lanes). Arrows indicate the positions of the unconjugated form of endogenous SUMO-2 and tagged forms of SUMO-2.
of free YFP-SUMO-2 compared with free His 6 -SUMO-2 (Fig. 1,  B and C) . We could not distinguish whether this was because of a higher conjugation efficiency for the smaller His 6 -SUMO-2 construct or, conversely, because of a higher rate of deconjugation for YFP-SUMO-2.
The fluorescence microscopy analysis showed that both endogenous and exogenous SUMO-2 were predominantly nuclear and showed accumulation in subnuclear bodies (Fig. 2, arrows) . The preferential nuclear localization of SUMO-2 was also supported by biochemical fractionation analysis (data not shown). A subset of the subnuclear bodies containing YFP-SUMO-2 were not labeled with anti-SUMO-2 antibody. This was not due to improperly expressed YFP species because immunoblotting analysis showed that there was little if any YFP that was not fused to SUMO-2 ( Fig. 1) (data not shown) . Therefore, analysis by immunofluorescence alone may not reveal the full range of nuclear structures containing SUMO-2. Most of the nuclear bodies containing SUMO-2 colocalized with PML bodies, as determined by double labeling with anti-PML antibody (Fig. 3) .
In summary, we conclude that epitope-tagged forms of SUMO-2 are functional. Based upon in vivo localization patterns and the range of high molecular mass SUMO-2 conjugates detected for both tagged and endogenous forms, we anticipate that the tagged exogenous SUMO-2 molecules are conjugated to a similar range of cellular target proteins compared with endogenous SUMO-2.
Enrichment of SUMO-2 Conjugates-Our next aim was to identify cellular proteins that are conjugated to SUMO-2. To identify SUMO-2 targets, we exploited the HeLa His6-SUMO-2 cell line. Conjugation of His 6 -SUMO-2 covalently linked the His 6 affinity tag to the target protein, thereby allowing its purification using a Ni 2ϩ -agarose column. To enhance the purification of SUMO-2 conjugates, we took advantage of the fact that SUMO-2 accumulates in PML bodies. We therefore performed affinity purification on nuclear fractions enriched for PML bodies and other subnuclear structures (see "Experimental Procedures"). Briefly, nuclei were isolated by centrifugation and treated with DNase I to digest the chromatin, which was then removed by sequential washing with buffers of increasing salt concentrations (shown as a schematic in Fig. 4A ). In parallel, we performed an identical fractionation with the HeLa EYFP-SUMO-2 cell line and analyzed the resulting fractions by fluorescence microscopy to detect YFP-SUMO-2. This showed that, in the isolated fractions, intact nuclear bodies containing YFP-SUMO-2 were present (Fig. 4B) . Additionally, immunoblot analysis confirmed that PML was enriched ϳ20-fold in the final nuclear fraction (Fig. 4C) .
Large-scale Ni 2ϩ -agarose affinity purification was then per-
FIG. 2. SUMO-2 is a nuclear protein that accumulates in nuclear bodies. A, HeLa
EYFP-SUMO-2 cells were fixed, permeabilized, and stained with DAPI to label DNA (blue) and with polyclonal antibody 2277 to detect SUMO-2 (red). Nuclear bodies were enriched for SUMO-2 (green) as indicated by the arrows. Scale bar ϭ 5 m. B, HeLa His6-SUMO-2 cells were fixed, permeabilized, and stained with DAPI to label DNA (blue). Immunofluorescence analysis was performed to detect the His 6 tag (green) and SUMO-2 (red). Nuclear bodies were enriched for SUMO-2 as indicated by the arrows. Scale bar ϭ 5 m.
FIG. 3. SUMO-2 colocalizes with PML in nuclear bodies. A, HeLa
EYFP-SUMO-2 cells were fixed, permeabilized, and stained with DAPI to detect DNA (blue) and with a monoclonal antibody to detect PML (red). EYFP-SUMO-2 (green) colocalized with PML in nuclear bodies as indicated by the arrows. Not all EYFP-SUMO-2-positive nuclear bodies were enriched for PML as indicated by the arrowheads. Scale bar ϭ 5 m. B, HeLa cells were fixed, permeabilized, and stained with DAPI to detect DNA (blue). Immunofluorescence analysis was performed to detect PML (green) and SUMO-2 (red). Nuclear bodies are indicated by arrows. Scale bar ϭ 5 m.
formed on equal amounts of PML-enriched fractions from both the control HeLa and HeLa His6-SUMO-2 cells (Fig. 4, D and E) . The affinity-purified proteins were separated by SDS-PAGE; transferred to a membrane; and probed with an antibody to detect SUMO-2, which showed that the procedure specifically enriched for SUMO-2 conjugates from the HeLa His6-SUMO-2 cell line (Fig. 4E) .
Identification of SUMO-2 Conjugates by Mass Spectrometry-To identify endogenous SUMO-2-conjugated proteins, affinity-purified fractions from both the control HeLa and
HeLa
His6-SUMO-2 cells were digested with trypsin, and the resulting peptides were separated by HPLC and analyzed by tandem mass spectrometry. The control HeLa fractions were analyzed to identify fortuitously co-purifying proteins without a His 6 -SUMO tag and hence to eliminate false positive targets. Eleven unique proteins enriched in the purified fraction derived from the HeLa His6-SUMO-2 cells were identified by at least two peptides (Table I) . A list of all identified peptides from both control and His 6 -SUMO-2 fractionations can be found in Supplemental Table A . FIG. 4 . Affinity isolation of SUMO-2 conjugates. A, schematic showing an outline of the nuclear body enrichment procedure (see "Experimental Procedures"). Nuclei were isolated from trypsinized cells and treated with DNase I. Chromatin was removed using wash buffers containing 250 mM (NH 4 ) 2 SO 4 and 1 M NaCl or 2 M NaCl. PBS, phosphatebuffered saline. B, nuclear bodies are retained in the isolated nuclear fraction from HeLa EYFP-SUMO-2 cells. Nuclear bodies derived from HeLa EYFP-SUMO-2 cells were attached to poly-L-lysine-coated slides and analyzed by fluorescence microscopy to detect EYFP-SUMO-2. Scale bar ϭ 5 m. C, the isolated nuclear fraction is enriched for the nuclear body marker PML. Equal amounts of whole cell extract and extract from the enriched nuclear fraction were fractionated by SDS-PAGE, transferred to a membrane, and probed using monoclonal antibody 5E10 to detect PML. D, control showing equivalent amounts of total protein input from HeLa His6-SUMO-2 and control HeLa cells that were subjected to the affinity isolation procedure. Isolated nuclear fractions from the HeLa His6-SUMO-2 and control HeLa cells were solubilized in 8 M urea. Equal amounts of lysates were separated by SDS-PAGE, transferred to a membrane, and analyzed both by Ponceau S staining and by probing with antibody 5E10 to detect PML. E, affinity-enriched SUMO-2 conjugates. Nuclear fractions isolated from either HeLa His6-SUMO-2 or control parental HeLa cells were prepared. His 6 -SUMO-2 conjugates were purified on Ni 2ϩ -agarose, separated by SDS-PAGE, transferred to a membrane, and probed using polyclonal antibody NRD.1 to detect SUMO-2.
In principle, 10 of the proteins listed in Table I are candidate SUMO-2 targets, including both SUMO-2 and SUMO-3, due to the presence of an internal consensus sumoylation site (59) . We have the most confidence in the nine proteins in this list that contain one or more consensus sumoylation motifs and that lack obvious histidine-rich regions that could result in their fortuitous co-purification (shown in boldface in Table I ). However, Chromobox homolog-4 contains a histidine-rich region in addition to a consensus sumoylation motif. Nonetheless, it represents a genuine target for other SUMO family members, as recently shown (36) . We identified peptides in the purified fraction from SUMO-2, as expected. The next step was to determine whether the proteins identified using this purification strategy include bona fide SUMO-2 targets.
Confirmation of SART1 and hnRNP M as Bona Fide Targets for SUMO-2 Modification-SART1
and hnRNP M were selected for further characterization because both proteins contain consensus sumoylation motifs and lack histidine-rich regions. In addition, both are RNA-binding proteins that are likely to be involved in RNA processing and/or transport, suggesting the possibility of a role for SUMO-2 modification in these processes.
A combination of in vivo and in vitro experiments were performed to assess whether SART1 and hnRNP M represent bona fide SUMO-2 targets. First, we constructed an epitopetagged SART1 expression vector, pEYFP-SART1 (see "Experimental Procedures"), with EYFP fused to the N terminus of SART1. Both HeLa His6-SUMO-2 and control HeLa cells were transiently transfected with pEYFP-SART1, and the His 6 -SUMO-2 conjugates were purified from isolated nuclei of transfected cells by affinity chromatography using Ni 2ϩ -agarose (Fig. 5A) . Proteins either present in the total nuclear lysate (lanes 1 and 2) or purified by Ni 2ϩ -agarose chromatography (lanes 3 and 4) were separated by SDS-PAGE, transferred to a membrane, and probed using a monoclonal antibody that detects YFP. The transiently expressed YFP-SART1 construct was detected in both the control and HeLa His6-SUMO-2 extracts as an ϳ100-kDa band. However, at least two slower migrating bands, consistent with the conjugation of one and two molecules of SUMO to SART1, were detected specifically in the affinity-purified fraction from the HeLa His6-SUMO-2 cells (lane 4). Further evidence that SART1 is a target for SUMO-2 was provided by in vitro sumoylation assay (Fig. 5B) . In this assay, in vitro translated, untagged SART1 was incubated with puri- His6-SUMO-2 and control HeLa cells were transfected with an expression construct encoding EYFP-SART1. Nuclei were isolated and lysed in 8 M urea, and His 6 -SUMO-2 conjugates were purified on Ni 2ϩ -agarose. Purified fractions were separated by SDS-PAGE, transferred to a membrane, and probed using a monoclonal antibody to detect EYFP. B, SART1 is sumoylated in vitro. An in vitro SUMO-2 conjugation reaction was performed with recombinant SUMO-2, recombinant E1 (SAE1/2), and recombinant E2 (Ubc9) plus in vitro transcribed and translated 35 S-labeled SART1. Controls lacking SUMO-2 and/or Ubc9 were included (lanes 1-3) . The reaction mixture was incubated for 3 h at 37°C before addition of SDS sample buffer to halt reaction progress. Samples were fractionated by SDS-PAGE, and dried gels were analyzed to detect radiolabeled species. The positions of the SUMO-2 conjugates and free SART1 are indicated. C, hnRNP M is sumoylated in vivo. Nuclei were prepared from both HeLa His6-SUMO-2 and control HeLa cells. His 6 -SUMO-2 conjugates were purified on Ni 2ϩ -agarose, separated by SDS-PAGE in nonadjacent lanes, transferred to a membrane, and probed to detect hnRNP M. The figure is composed of input lanes from short exposures and pull-down lanes from longer exposures of the same blot. fied recombinant conjugation enzymes and SUMO-2, which showed that SUMO-2 could be conjugated efficiently to SART1 (Fig. 5B) . It is not clear from both the in vitro and in vivo assays whether SART1 uses more than one sumoylation site or, instead, if multiple SUMO molecules are added to the same lysine. However, the data strongly support that SART1 is a genuine SUMO-2 target. We next used anti-hnRNP M monoclonal antibody to detect endogenous hnRNP M in affinity-purified fractions enriched for His 6 -SUMO-2 conjugates from HeLa His6-SUMO-2 cells (Fig.  5C) . The results showed a major band of the expected size for SUMO-2-conjugated hnRNP M specifically in the SUMO-enriched fraction, as well as higher forms that likely correspond to multiply sumoylated forms of hnRNP M (lane 4). Further analysis showed that the monosumoylated band was a doublet that may correspond to the two major spliced forms of hnRNP M (which differ by 11 amino acids). These data strongly support that hnRNP M, like SART1, is a genuine SUMO-2 target. Taken together, the confirmation of both SART1 and hnRNP M as bona fide SUMO targets in vivo allows us to conclude that the affinity purification strategy we described here using HeLa His6-SUMO-2 cells successfully identifies endogenous sumoylated targets. DISCUSSION We have constructed and characterized stable HeLa cell lines that express either YFP-or His 6 -tagged SUMO-2 molecules to study the cellular localization of SUMO-2 and to identify target proteins for SUMO-2 conjugation. The data show that the tagged SUMO-2 molecules are functional and found at the same intracellular sites as endogenous SUMO-2, concentrating predominantly in the nucleus and showing enrichment in nuclear bodies. The conjugation of His 6 -SUMO-2 introduced an affinity tag to the target proteins. This was exploited to enrich for SUMO-2 conjugates, which were subsequently identified by mass spectrometry. A similar approach has recently been used to identify large numbers of ubiquitin targets in yeast (66) . Despite the well known problems in recovering SUMO conjugated to target proteins due to the high activity of SUMO-specific proteases, this affinity protocol results in high levels of conjugates relative to free forms of SUMO. The protocol thus provides an unbiased procedure for the systematic proteomic analysis of SUMO targets. A detailed analysis of the full range of SUMO target proteins is likely to be important for evaluating the biological significance of SUMO conjugation.
Among the novel proteins identified here as putative SUMO-2 targets, we have analyzed two in detail and confirmed that both of these, i.e. SART1 and hnRNP M, are conjugated to SUMO-2 in affinity-purified nuclear lysates. Both of these are nuclear RNA-binding proteins that may have roles in RNA processing and/or transport. For example, SART1 has been shown to be a component of the U4/U5/U6 small nuclear ribonucleoprotein subunit of the spliceosome (67) . There is also evidence that hnRNP M may have a role in splicing (68) , and both proteins have been detected as components of affinitypurified mammalian splicing complexes (69 -71) . Consistent with this, we detected exogenously expressed YFP-tagged SART1 localized in nuclear splicing speckles (data not shown). In this regard, it is interesting that the SUMO E3 ligase PIAS1 was also identified co-purifying with mammalian spliceosomes (70) . These results raise the possibility that sumoylation of splicing factors may influence one or more steps in the splicing mechanism.
The mass spectrometry analysis detected both SUMO-1 and SUMO-3 in the affinity-purified SUMO-2 conjugates. Due to the denaturing buffer conditions used, this implies that single target proteins can simultaneously be conjugated to multiple SUMO family members. This could occur via independent lysines on target proteins, but also via SUMO chain formation due to the presence of internal sumoylation sites in SUMO-2 and SUMO-3 (59). SUMO-1 lacks an internal sumoylation site and could therefore be present at the distal end of poly-SUMO chains.
In line with our results, SUMO-2 was recently identified in a purified SUMO-1 fraction (72) . In this study, hemagglutinin-SUMO-1 was used in an unbiased approach to identify SUMO-1 targets. Many of the identified potential SUMO-1 target proteins play a role in gene expression. Interestingly, zinc finger proteins and BTB-like domain proteins were identified in both screens.
The absence of PML in the list of proteins we identified here and the fact that we have so far screened only one nuclear fraction indicate that use in the future of higher sensitivity mass spectrometry techniques and analysis of additional nuclear fractions will likely identify many additional SUMO targets. It will also be interesting in the future to extend the approach with the HeLa His6SUMO-2 cell line to include the analysis of target proteins that are sumoylated only either under specific metabolic conditions (e.g. stress, DNA damage, etc.) or at defined stages of the cell cycle. In this regard, it is interesting that Azuma et al. (63) have recently identified an M phasespecific conjugation of topoisomerase II with SUMO-2 in Xenopus. Analysis of other subcellular fractions apart from the nuclear fractions analyzed here may also expand the number of SUMO-2 target proteins that can be identified. A similar approach can be used to detect cell type-specific factors that are SUMO-2 targets by expressing the His 6 -SUMO-2 molecule in other cell lines.
